Imagine being at higher risk for HIV but not having the conversation with your doctor that could protect you. That's the reality for many transgender women, a group disproportionately affected by HIV. A recent study tried to understand if transgender women who report behaviors associated with acquiring HIV were more likely to have talked with their clinician about PrEP—a daily pill that prevents HIV—or to have used it.
The research was observational, meaning it looked at patterns in existing data rather than testing an intervention. It involved transgender women without HIV infection across seven urban areas in the United States. The study specifically asked whether reporting certain risk behaviors was linked to having more discussions about PrEP or actually using it.
Here's the catch: the study's main results weren't reported. We don't know what the researchers found about these connections. Because it was an observational study, even if a link were found, it couldn't prove that the risk behaviors caused more conversations or PrEP use—it could only show an association. The findings, whatever they are, remain unknown, leaving us without clear answers about whether the healthcare system is reaching those who might need prevention most.
